Research reference · 10 mg vial

Semaglutide (10 mg Vial) Dosage Protocol

Written by PeptideDosages Editorial Team Published Updated

Semaglutide Dosage calculations for a 10 mg vial use the same once-weekly escalation amounts evaluated in human research and listed in the current injectable product information. Adding 3 mL in this lyophilized-vial calculation produces 3.33 mg/mL, so each U-100 unit contains 33.33 mcg.

On this page
  1. Quick reference
  2. Dosage chart and four steps
  3. Supplies needed
  4. Vial and research context
  5. Protocol Overview
  6. Dosing Protocol
  7. Storage Instructions
  8. Important Notes
  9. How This Works
  10. Clinical Benefits
  11. Side Effects
  12. Lifestyle Factors
  13. Injection Technique
  14. Important Research Note
  15. References
  16. Related Dosage Protocols

Semaglutide Quick Reference (10 mg Vial)

Vial contents
10 mg Semaglutide
Final volume
3 mL
Concentration
3.33 mg/mL
One U-100 unit
33.33 mcg in 0.01 mL
Semaglutide (10 mg Vial) peptide vial

Research context: For mechanisms, human research, outcomes, limitations, and safety context, read the Semaglutide Peptide research overview.

Semaglutide Dosage Chart (10 mg Vial)

The same published weekly escalation schedule converted for a 10 mg vial

Standard Weekly Escalation Schedule (3 mL = 3.33 mg/mL)

Study PhaseWeekly AmountU-100 UnitsVolume
Weeks 1 to 4 0.25 mg 7.5 units 0.075 mL
Weeks 5 to 8 0.5 mg 15 units 0.15 mL
Weeks 9 to 12 1 mg 30 units 0.3 mL
Weeks 13 to 16 1.7 mg 51 units 0.51 mL
Weeks 17+ 2.4 mg 72 units 0.72 mL

Frequency: Once weekly by subcutaneous administration. The current injectable semaglutide schedule starts at 0.25 mg for four weeks, then increases at four-week intervals to 0.5 mg, 1 mg, and 1.7 mg. The usual recommended adult weight-reduction maintenance amount is 2.4 mg once weekly.[1][2][3][4]

Reconstitution Steps

  1. Clean the vial stopper and gather the sterile supplies required by the research procedure.
  2. Add 3 mL of the documented sterile diluent slowly down the vial wall.
  3. Gently swirl or roll until dissolved. Do not shake.
  4. Label the vial 3.33 mg/mL with the preparation date and follow the exact formulation storage and discard instructions.

The weekly amounts remain identical across the Semaglutide family. The 10 mg vial changes only concentration, U-100 units, volume, and supply calculations.

Supplies Needed

Clear 12-week and 24-week planning for a 10 mg vial at 3.33 mg/mL.

  • Semaglutide vials (10 mg each):
    • 12-week schedule: 1 vial needed. Total scheduled amount: 7 mg.
    • 24-week schedule: 4 vials needed. Total scheduled amount: 33 mg.
  • U-100 insulin syringes (1 mL capacity):
    • 12-week schedule: 12 new syringes needed.
    • 24-week schedule: 24 new syringes needed.
  • Documented sterile diluent (10 mL bottles):
    • 12-week schedule: 1 bottle needed. Total diluent volume: 3 mL.
    • 24-week schedule: 2 bottles needed. Total diluent volume: 12 mL.
  • Alcohol swabs:
    • 12-week schedule: 24 swabs minimum. 1 box of 100 covers this minimum.
    • 24-week schedule: 48 swabs minimum. 1 box of 100 covers this minimum.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial, syringe, swab, and diluent totals are minimum arithmetic quantities for the standard schedule shown. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Semaglutide 10 mg

Semaglutide 10 mg

Research-labeled vial
U-100 syringes

U-100 syringes

View Supplier
Bacteriostatic water

Bacteriostatic water

View Supplier
Alcohol swabs

Alcohol swabs

View Supplier

Semaglutide Vial and Research Context

  • Reconstitute: Add 3 mL of the documented sterile diluent to produce 3.33 mg/mL.
  • Research frequency: Once weekly by subcutaneous administration in the cited human trials.[1][2][3][4]
  • Weekly research range: The standard schedule shown below progresses from 0.25 mg to 2.4 mg weekly in four-week stages.[1][2][3][4]
  • Easy measuring: 1 U-100 unit = 0.01 mL = 33.33 mcg.
  • Vial size: The 10 mg label is total nominal vial content, not a weekly amount.
  • Vial coverage: At the 0.25 mg starting stage, one vial supplies 40 full weekly amounts. At the 2.4 mg maintenance stage, one vial supplies 4 full weekly amounts with 0.4 mg remaining. These are mass calculations, not vial storage or discard periods.

Protocol Overview

Quick reference for the shared Semaglutide escalation schedule.

  • Route: Subcutaneous administration in the cited trials.[1][2][3][4]
  • Frequency: Once weekly.
  • Standard schedule: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then the usual 2.4 mg adult weight-reduction maintenance amount.[1][2][3][4]
  • Concentration: 10 mg divided by 3 mL equals 3.33 mg/mL.
  • Unit conversion: 1 U-100 unit equals 33.33 mcg.

Dosing Protocol

The table converts one shared schedule for this vial concentration.

  • Weeks 1 to 4: 0.25 mg once weekly.[1]
  • Weeks 5 to 8: 0.5 mg once weekly.[1]
  • Weeks 9 to 12: 1 mg once weekly.[1]
  • Weeks 13 to 16: 1.7 mg once weekly.[1]
  • Week 17 onward: The usual recommended adult weight-reduction maintenance amount is 2.4 mg once weekly.[1]
  • Consistency: Vial size does not change the weekly schedule.

Storage Instructions

Use the storage directions for the exact supplied formulation.

  • Before preparation: Keep the vial dry, protected from light, and stored according to its documentation.
  • After preparation: Refrigerate only as permitted by the exact formulation and diluent instructions.
  • Labeling: Record the concentration, preparation date, storage conditions, and documented discard date.
  • Handling: Avoid unnecessary agitation and follow the exact product instructions.

Important Notes

Practical details for reading the schedule and vial calculations consistently.

  • The weekly amounts are identical across every Semaglutide vial-size page. Only concentration, volume, U-100 units, and supply totals change.
  • The injectable schedule uses four-week escalation steps before the usual 2.4 mg adult weight-reduction maintenance amount.[1][2][3][4]
  • The current label also allows an increase to 7.2 mg once weekly after at least four weeks at 2.4 mg when additional weight reduction is clinically indicated; that optional amount is not included in the standard table or supply totals.[1][8]
  • Use a new sterile syringe for each injection and place used sharps in an appropriate container.[11][12]
  • Record the weekly amount, calculated units, volume, date, and administration site consistently.

How This Works

Semaglutide is a GLP-1 receptor agonist studied with once-weekly subcutaneous schedules in controlled human trials.[1][2][4][9]

  • GLP-1 receptor activity contributes to glucose-dependent insulin signaling, glucagon regulation, appetite signaling, and caloric intake.[1][9]
  • The extended pharmacokinetic profile supports once-weekly administration in the cited clinical programs.[1][2][4][9]
  • The published trials evaluated manufactured study products with structured escalation and monitoring plans.[2][3][4][5]

Clinical Benefits

Results below summarize observations from controlled human research.

  • STEP 1 reported clinically meaningful body-weight reductions with 2.4 mg once-weekly semaglutide plus lifestyle intervention through 68 weeks.[2][3]
  • STEP 2 reported body-weight improvement in adults with overweight or obesity and type 2 diabetes at the studied 2.4 mg weekly target.[4]
  • STEP 4 reported continued weight reduction when weekly 2.4 mg treatment continued after the 20-week run-in period.[5][10]
  • SELECT and SUSTAIN-6 evaluated cardiovascular outcomes in distinct high-risk study populations.[6][7]

Side Effects

Safety findings remain specific to the studied populations, products, schedules, and monitoring plans.

  • Gastrointestinal events, including nausea, diarrhea, vomiting, and constipation, were among the commonly reported events.[1][2][4][5]
  • Gradual escalation is used to reduce gastrointestinal adverse reactions in the current prescribing information.[1]
  • The current prescribing information includes contraindications, warnings, precautions, and interaction information that should be read in full.[1]
  • Trial results should be compared within the same population, target amount, follow-up period, and analysis plan.

Lifestyle Factors

Consistent study conditions make weekly observations easier to interpret.

  • Record diet, physical activity, sleep, hydration, and gastrointestinal observations consistently.
  • Use the same body-weight, waist, glucose, and laboratory measurement methods throughout the observation period.
  • Compare results within the same population, target amount, follow-up period, and analysis plan.

Injection Technique

General subcutaneous research technique should follow the approved institutional or laboratory procedure.[11][12]

  • Use a new sterile syringe and needle for every injection and each separate vial entry.
  • Clean the vial stopper and selected site, then allow the surface to dry.
  • Use the needle length, angle, and skinfold method specified by the governing procedure.
  • Rotate sites systematically and document each administration.
  • Place used sharps immediately in an appropriate sharps container.

Important Research Note

This page pairs the published Semaglutide weekly schedule with transparent arithmetic for a nominal 10 mg lyophilized vial. The cited trials and current product label used manufactured dosage forms under structured monitoring.

References

  • 1
    FDA (2026): Wegovy semaglutide injection and tablets: current prescribing information
    View Source
  • 2
    New England Journal of Medicine (2021): Once-weekly semaglutide in adults with overweight or obesity: STEP 1
    View Source
  • 3
    ClinicalTrials.gov: STEP 1 study record NCT03548935
    View Source
  • 4
    The Lancet (2021): Semaglutide 2.4 mg once weekly in adults with overweight or obesity and type 2 diabetes: STEP 2
    View Source
  • 5
    JAMA (2021): Continued weekly subcutaneous semaglutide and weight-loss maintenance: STEP 4
    View Source
  • 6
    New England Journal of Medicine (2023): Semaglutide and cardiovascular outcomes in obesity without diabetes: SELECT
    View Source
  • 7
    New England Journal of Medicine (2016): Semaglutide and cardiovascular outcomes in patients with type 2 diabetes: SUSTAIN-6
    View Source
  • 8
    The Lancet (2025): Once-weekly semaglutide 7.2 mg in adults with obesity: STEP UP
    View Source
  • 9
    Journal of Medicinal Chemistry (2015): Discovery of the once-weekly glucagon-like peptide-1 analogue semaglutide
    View Source
  • 10
    ClinicalTrials.gov: STEP 4 study record NCT03548987
    View Source
  • 11
    CDC: Preventing unsafe injection practices and handling multidose vials
    View Source
  • 12
    NCBI Bookshelf: Best practices for injections and related procedures
    View Source

Related Dosage Protocols

Compare the other Semaglutide vial sizes and practical measurement guides.

Semaglutide Peptide Research OverviewSemaglutide 5 mg Vial Dosage ProtocolSemaglutide 15 mg Vial Dosage ProtocolSemaglutide 20 mg Vial Dosage ProtocolSemaglutide 30 mg Vial Dosage ProtocolPeptide Dosage ChartPeptide Reconstitution GuideSyringe and Measurement Guide